PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
Takeda in Talks with Shire after 3 Buyout Proposals Rejected
Takeda Pharmaceutical has made three proposals to London-listed Shire regarding its potential offer for the Dublin maker, which were all rejected, the two companies revealed on April 19, confirming earlier reports by Reuters. Their talks are still ongoing, they said.…
To read the full story
Related Article
- Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
June 29, 2018
- Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Takeda’s Founding Family-Backed Shareholders Demand Prior Vote for 1 Trillion Yen-Plus Deals
June 6, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
- Takeda Mulls Takeover Bid for Shire
March 29, 2018
BUSINESS
- Wholesalers See NHI-Market Price Gap Falling Below 4.8% to New Record Low
October 26, 2026
- Vyepti Could Expand Migraine Treatment Options: Japanese Expert
October 26, 2026
- Zeria to Buy German Asacol Manufacturing Partner
October 26, 2026
- Otsuka’s IgAN Drug Voyxact Cuts Kidney Event Risk by 97%
October 26, 2026
- NEC’s Neoantigen Therapy Shows Immunogenicity in Early TNBC Trial
October 26, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…